Financial Performance - Gross premiums written for Q3 2025 reached $1,752.6 million, an increase from $1,663.4 million in Q3 2024, representing a growth of 5.4% year-over-year[8] - Net income for Q3 2025 was $178.7 million, compared to $102.1 million in Q3 2024, reflecting a significant increase of 75.7%[8] - Operating income after taxes for Q3 2025 was $185.6 million, up from $111.3 million in Q3 2024, marking a growth of 66.7%[8] - Total revenues for the nine months ended September 30, 2025, reached $4,922.6 million, reflecting a 5.8% increase from $4,653.1 million in the same period of 2024[11] - Net income for Q3 2025 was $178.7 million, a significant increase of 75.0% from $102.1 million in Q3 2024[11] - The company reported a net income of $464.0 million for the nine months ended September 30, 2025, compared to $258.1 million for the same period in 2024, reflecting a year-over-year increase of 79.5%[56] Assets and Equity - Total assets as of September 30, 2025, were $16,774.2 million, an increase from $15,367.0 million as of December 31, 2024, indicating a growth of 9.2%[8] - Total shareholders' equity increased to $3,426.3 million as of September 30, 2025, compared to $2,877.7 million as of September 30, 2024, representing a growth of 19.1%[8] - Cash and cash equivalents surged by 110.3% to $915.7 million compared to $435.5 million at the end of 2024[14] - Total liabilities increased by 7.4% to $13,347.9 million as of September 30, 2025, from $12,432.7 million at the end of 2024[14] - Retained earnings grew by 11.5% to $3,577.3 million as of September 30, 2025, compared to $3,209.6 million at the end of 2024[14] Premiums and Underwriting - The company reported net premiums earned of $1,550.7 million in Q3 2025, up from $1,479.2 million in Q3 2024, a growth of 4.8%[8] - Premiums earned for Q3 2025 increased to $1,550.7 million, a 4.8% rise from $1,479.2 million in Q3 2024[11] - Gross premiums written increased to $5,356.0 million in 2025 from $5,136.7 million in 2024, representing a growth of 4.3%[18] - Net premiums written rose to $4,833.5 million in 2025, up from $4,638.5 million in 2024, indicating an increase of 4.2%[18] - Net premiums earned reached $4,604.5 million in 2025, compared to $4,401.0 million in 2024, reflecting a growth of 4.6%[18] Investment Income - Net investment income rose by 27.5% to $117.0 million in Q3 2025, compared to $91.8 million in Q3 2024[11] - Net investment income increased to $328.6 million in 2025, compared to $271.9 million in 2024, showing a growth of 20.8%[18] - The total net investment income for Q1 2025 is projected to be $106.1 million, up from $100.7 million in Q4 2024, indicating a growth of 4.3%[44] - The pre-tax yield for total investments is expected to increase to 4.14% in Q1 2025 from 3.97% in Q4 2024, reflecting a positive trend in investment performance[44] Ratios and Performance Metrics - The premium to surplus ratio improved to 1.92:1 as of September 30, 2025, down from 2.07:1 a year earlier, indicating enhanced financial strength[8] - The combined ratio for Q3 2025 was 97.3%, compared to 84.9% in Q3 2024, indicating a decline in underwriting performance[16] - The combined ratio for 2025 was 92.6%, an improvement from 96.7% in 2024, indicating enhanced operational efficiency[21] - The loss and LAE ratio for 2025 was 61.7%, an improvement from 65.8% in 2024, indicating better loss management[21] - The expense ratio remained stable at 30.9% for both 2024 and 2025, reflecting consistent cost management[21] Catastrophe Losses - Current year catastrophe losses for 2025 were $267.3 million, down from $386.9 million in 2024, a decrease of 30.8%[18] - Current year catastrophe losses for Q1 2024 amounted to $24.5 million, contributing to total losses and LAE of $320.9 million[23] - Current year catastrophe losses for Q1 2025 amounted to $17.2 million, compared to $10.2 million in Q1 2024[28] - The current year catastrophe losses accounted for 6.9% of total losses in 2025, down from 13.6% in 2024[36] Stock and Dividends - The Hanover reported a quarterly dividend of $0.900 per share for Q3 2025, compared to $0.850 per share for the same quarter in 2024[69] - The stock price range for Q3 2025 was between $162.08 and $182.10, reflecting an increase from the previous year's range of $123.93 to $149.58[69] - The Hanover's financial strength ratings include an A rating from A.M. Best and a BBB rating from S&P Global[70] - The company’s common stock is traded on the New York Stock Exchange under the symbol "THG"[71] Strategic Focus - The company continues to focus on expanding its core commercial and specialty segments, targeting growth in specific industry sectors[5] - Future outlook suggests continued growth in net premiums written, with a projected increase of 3.9% for the full year 2025[25]

Franklin BSP Realty Trust, Inc. Announces Third Quarter 2025 Results Investor Relations Contact: Lindsey Crabbe l.crabbe@benefitstreetpartners.com (214) 874-2339 New York City, NY – October 29, 2025 – Franklin BSP Realty Trust, Inc. (NYSE: FBRT) ("FBRT" or the "Company") today announced financial results for the quarter ended September 30, 2025. Reported GAAP net income of $17.6 million for the three months ended September 30, 2025, compared to $24.4 million for the three months ended June 30, 2025. Reporte ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31567 CENTRAL PACIFIC FINANCIAL CORP. (Exact name of registrant as specified in its charter) (State or oth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 1-15579 MSA SAFETY INCORPORATED (Exact name of registrant as specified in its charter) Pennsylvania 46-4914539 (State or other jurisdiction of incorporation or organiz ...

Exhibit 99.1 UNITED STATES LIME & MINERALS, INC. — NEWS RELEASE FOR IMMEDIATE RELEASE Contact: Timothy W. Byrne (972) 991-8400 UNITED STATES LIME & MINERALS REPORTS THIRD QUARTER 2025 RESULTS AND DECLARES REGULAR QUARTERLY CASH DIVIDEND Dallas, Texas, October 29, 2025 - United States Lime & Minerals, Inc. (NASDAQ: USLM) today reported third quarter 2025 results: The Company's revenues in the third quarter 2025 were $102.0 million, compared to $89.4 million in the third quarter 2024, an increase of $12.6 mil ...

Financial Performance - BridgeBio generated net product revenue of $216.4 million during the nine months ended September 30, 2025[303]. - The company incurred net losses of $538.3 million and $276.0 million for the nine months ended September 30, 2025 and 2024, respectively[306]. - Total revenues, net for the three months ended September 30, 2025, increased by $118.0 million to $120.7 million compared to the same period in 2024, driven by a $108.1 million increase in net product revenue[318]. - Net product revenue for the three and nine months ended September 30, 2025, was $108.1 million and $216.4 million, respectively, generated from the commercial sale of Attruby in the U.S. following FDA approval in November 2024[319]. - The net loss attributable to common stockholders for the three months ended September 30, 2025, was $182.7 million, compared to a net loss of $162.0 million in the same period of 2024[316]. - For the nine months ended September 30, 2025, the company incurred a net loss of $538.3 million, compared to $276.0 million for the same period in 2024, representing a 95.0% increase in losses year-over-year[351]. Revenue Sources - The company anticipates future revenue to primarily be generated from recurring net product revenue following the commercialization of Attruby and significant future royalty revenue from Beyonttra sales[323]. - License and services revenue for the three months ended September 30, 2025, increased by $5.6 million, while for the nine months, it decreased by $90.6 million due to prior year recognition of $205.3 million in upfront license fees[321]. - Royalty revenue for the three and nine months ended September 30, 2025, was $4.3 million and $6.1 million, respectively, related to sales of Beyonttra in the EU and Japan following regulatory approvals[322]. Expenses and Losses - The company expects to continue incurring operating and net losses for at least the next several years[306]. - Selling, general and administrative expenses increased by $68.8 million (100.0%) for the three months ended September 30, 2025, and by $179.0 million (91.9%) for the nine months ended September 30, 2025, compared to the same periods in 2024[333][335]. - The increase in selling, general and administrative expenses for the three months was primarily driven by a $43.4 million increase in external costs and an $18.5 million increase in personnel-related expenses[334]. - Research and development expenses decreased by $7.6 million for the three months and $40.6 million for the nine months ended September 30, 2025, compared to the same periods in 2024, mainly due to reprioritization of R&D programs[328]. Cash Flow and Liquidity - Cash, cash equivalents, and marketable securities as of September 30, 2025, totaled $645.9 million, down from $681.1 million as of December 31, 2024[317]. - The company reported net cash used in operating activities of $389.5 million for the nine months ended September 30, 2025, primarily due to a net loss of $538.3 million[396]. - The company experienced a net cash outflow of $100.7 million related to changes in operating assets and liabilities, mainly due to an increase in accounts receivable[396]. - Net cash used in investing activities was $10.1 million for the nine months ended September 30, 2025, primarily due to purchases of marketable securities of $10.9 million[398]. Debt and Financing - The company had cash, cash equivalents, and marketable securities totaling $645.9 million as of September 30, 2025, while outstanding debt stood at $1.9 billion[350]. - The principal balances of the company's 2031 Notes, 2029 Notes, and 2027 Notes were $575.0 million, $747.5 million, and $550.0 million, respectively, with fixed interest rates[406]. - The company issued $550.0 million of 2027 Notes in March 2020, with net proceeds of approximately $537.0 million after expenses[373]. - The Bayer License Agreement entitles BridgeBio to an upfront payment of $135.0 million and potential milestone payments up to $600.0 million through 2026[312]. Regulatory and Product Development - BridgeBio has created 19 Investigational New Drug applications (INDs) and received FDA approval for three products since its inception in 2015[301]. - BridgeBio's commercial product, acoramidis, received FDA approval on November 22, 2024, and subsequent approvals in Europe and Japan[303]. - Product sales of Attruby, approved on November 22, 2024, are expected to provide a growing source of operating cash flow starting in 2025[394]. Other Financial Metrics - Interest income for the three months ended September 30, 2025, was $6.2 million, an increase of $2.9 million (88.2%) compared to $3.3 million in the same period in 2024[337]. - Interest expense decreased by $11.3 million (49.0%) for the three months ended September 30, 2025, totaling $(11.7) million compared to $(23.1) million in 2024[338]. - The company recognized a loss on extinguishment of debt of $21.2 million for the three months ended September 30, 2025, following the repayment of the term loan under the Amended Financing Agreement[344]. - Other income, net increased by $14.7 million (817.0%) for the three months ended September 30, 2025, totaling $16.5 million compared to $1.8 million in the same period in 2024[346].

Financial Performance - Q3 2025 sales reached $670 million, representing a core sales growth of 9.4% compared to Q3 2024[4] - Adjusted EBITDA for Q3 2025 was $97 million, reflecting a 77% year-on-year increase, with an adjusted EBITDA margin of 14.5% (+540 bps year-on-year)[4] - The company reported a GAAP net loss of $30 million for Q3 2025, attributed to a tax charge from restructuring intercompany loans[4] - Adjusted diluted earnings per share (EPS) for Q3 2025 was $0.32, a 167% increase year-on-year[4] - Operating cash flow for Q3 2025 was $79 million, while free cash flow was $68 million, compared to $71 million and $63 million in Q3 2024, respectively[5] - Net income for the nine months ended September 26, 2025, was $14.1 million, a significant recovery from a net loss of $1,119.8 million in the same period last year[19] - Adjusted net income for the nine months ended September 26, 2025, was $138.9 million, compared to $85.4 million for the same period last year, indicating a growth of 62.6%[21] - Adjusted diluted EPS guidance for 2025 is now set at $1.10 to $1.15, an increase from the prior guidance of $1.05 to $1.15[7] Cash Flow and Share Repurchase - The company repurchased 2.1 million shares for approximately $41 million during the quarter, with $108 million remaining under its stock repurchase program[6] - Free cash flow for the nine months ended September 26, 2025, was $139.2 million, down from $178.9 million in the prior year, a decrease of 22.2%[21] - Free Cash Flow (FCF) for the three months ended September 26, 2025, was $67.9 million, compared to $63.3 million for the same period in 2024, representing a 10.0% increase[31] Sales and Growth - For full year 2025, the company updated its core sales growth guidance to approximately 4%, up from the previous range of 3% to 4%[7] - All major businesses delivered positive growth, supported by several new product launches[4] - Specialty Products & Technologies segment sales for the three months ended September 26, 2025, were $431.5 million, up from $381.7 million in the same period last year, an increase of 13.1%[23] - Total sales growth for the three months ended September 26, 2025, was 11.5%, with core sales growth contributing 9.4%[30] Assets and Liabilities - Total assets increased to $5,642.5 million as of September 26, 2025, up from $5,350.5 million at December 31, 2024, reflecting a growth of approximately 5.5%[17] - Total liabilities decreased to $2,554.3 million as of September 26, 2025, from $2,516.0 million at December 31, 2024, a reduction of approximately 1.5%[17] Operating Performance - Gross profit for the three months ended September 26, 2025, was $370.2 million, compared to $317.3 million for the same period last year, representing a year-over-year increase of 16.7%[21] - Adjusted Operating Profit for the three months ended September 26, 2025, was $85.6 million, up from $43.8 million for the same period in 2024, representing a 95.7% increase[25] - Adjusted Net Income for the three months ended September 26, 2025, was $53.7 million, compared to $21.1 million for the same period in 2024, reflecting a 153.1% increase[26] - The operating margin for the total segment improved to 8.6% for the three months ended September 26, 2025, compared to 3.5% in the same period last year[23] Non-GAAP Measures and Adjustments - Adjusted EBITDA is used as a supplemental measure for assessing operating performance, excluding interest, taxes, depreciation, amortization, and unusual losses or gains[35] - Free Cash Flow (FCF) is utilized to evaluate the company's ability to generate cash for investments and growth, although it does not account for debt service requirements[36] - The company excludes amortization of acquisition-related intangible assets to facilitate consistent comparisons of operating results over time[37] - Core sales exclude the effects of acquisitions, divested product lines, discontinued products, and currency translation to provide a clearer view of ongoing operations[37] - Adjusted Net Income and Adjusted Diluted Earnings Per Share are calculated after excluding items that may obscure underlying business trends[37] - Management uses non-GAAP measures to evaluate operating and financial performance, highlighting the limitations of Free Cash Flow[36] - The company aims to provide investors with insights into long-term profitability trends compared to peers and historical performance[35]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 1-10485 TYLER TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) | Delaware 75-2303920 | | --- | | (State or other jurisdiction of (I.R.S. employer | | incorp ...

Exhibit 99.2 FORWARD-LOOKING STATEMENTS This supplemental information contains forward-looking statements within the meaning of the federal securities laws. You can identify these statements by our use of the words "assumes," "believes," "estimates," "expects," "guidance," "intends," "plans," "projects" and similar expressions that do not relate to historical matters. You should exercise caution in interpreting and relying on forward-looking statements because they involve known and unknown risks, uncertain ...

Revenue Growth - Total revenue increased by $63.5 million, or 9.7%, from $657.7 million in the nine months ended September 30, 2024, to $721.2 million in the same period in 2025[113] - Service revenue increased by $46.6 million, or 7.4%, to $678.6 million for the nine months ended September 30, 2025, compared to $632.0 million for the same period in 2024[152] - Total revenue for the three months ended September 30, 2025, was $261.9 million, a 16.1% increase from $225.6 million in Q3 2024[136] - Government Solutions service revenue rose by $17.3 million, or 19.0%, from $91.0 million in Q3 2024 to $108.3 million in Q3 2025, driven by installation service revenue from the NYCDOT red-light expansion program[137] - Product sales increased by $10.4 million, or 126.0%, from $8.3 million in Q3 2024 to $18.7 million in Q3 2025, primarily due to a $9.4 million increase in Government Solutions segment sales[139] - Product sales rose by $16.9 million, or 65.8%, to $42.6 million for the nine months ended September 30, 2025, driven by international product sales and red-light camera sales[156] Operating Performance - Cash flows from operating activities were $215.8 million for the nine months ended September 30, 2025, compared to $183.2 million for the same period in 2024[113] - Operating expenses increased by $21.5 million, or 9.7%, to $243.1 million for the nine months ended September 30, 2025, with a significant rise in the Government Solutions segment[159] - Operating expenses increased by $12.0 million, or 15.8%, from $76.0 million in Q3 2024 to $88.0 million in Q3 2025, with a notable increase in the Government Solutions segment[142] - Selling, general and administrative expenses increased to $147.7 million, but as a percentage of total revenue, it decreased from 21.7% to 20.5%[160] Net Income and Financial Health - Net income for the three months ended September 30, 2025, was $46.8 million, an increase of $12.1 million from $34.7 million in Q3 2024, attributed to higher service revenue and product sales[150] - Net income for the nine months ended September 30, 2025, was $117.8 million, a 20.0% increase from $98.1 million in 2024[166] - The company expects existing cash and cash equivalents, along with cash flows from operations, to meet operating cash requirements for at least the next 12 months[168] Debt and Interest Expense - Interest expense decreased by $7.6 million for the nine months ended September 30, 2025, due to debt refinancing[113] - Interest expense decreased by approximately $2.3 million from $18.7 million in Q3 2024 to $16.4 million in Q3 2025, due to a reduction in interest rates from debt refinancing[144] - Interest expense for the nine months ended September 30, 2025, was $49.6 million, down from $57.2 million in 2024[194] - The company refinanced the 2021 Term Loan, reducing the interest rate by 1.00% and eliminating the credit spread adjustment[172][183] - Each 1% movement in interest rates will result in an approximately $6.9 million change in annual interest expense based on the outstanding balance of the 2021 Term Loan[200] Investments and Financing - Entered into a $150 million senior secured asset-based revolving credit facility maturing on October 17, 2030[116] - The company amended the Revolver, increasing commitments from $125.0 million to $150.0 million and extending the maturity date to October 17, 2030[171][193] - Cash used in investing activities increased to $84.7 million in 2025 from $51.0 million in 2024, primarily due to increased purchases for the Government Solutions segment[180] - The company had $123.2 million available for borrowing under the Revolver as of September 30, 2025, with no outstanding borrowings[170][190] Market and Operational Developments - Installed 130 red-light cameras in New York City during Q3 2025, generating approximately $17.0 million in revenue[114] - NYCDOT identified the company as the vendor to manage New York City's automated enforcement camera safety programs for an expected five-year period[115] - TSA Passenger Volume increased by about 1% in Q3 2025 compared to the same period in 2024, indicating growth in travel demand[121] - The company’s Government Solutions segment relies on enabling legislation for photo enforcement programs, impacting revenue positively[123] - The Commercial Services segment's revenue is influenced by factors such as travel demand, economic conditions, and consumer confidence[120]